Intervention
Participants assigned to the intervention group received an event-triggered external loop recorder that automatically recorded episodes of AF by detection of R-R irregularity >30 beats at any ventricular rate (Braemar Inc, ER910AF). It was attached to a nonadhesive dry electrode belt worn around the chest (Accuheart Electrode Belt; Cardiac Bio-Systems, Inc). Participants were instructed to wear the monitor as much as possible for ≤30 days. The devices had a maximum memory storage capacity of 30 minutes and were programmed to record ≤2.5 minutes per episode. Recorded ECG data were transmitted transtelephonically for central physician interpretation.
Outcomes
We collected baseline Holter and echocardiogram reports from sites for central review. Automated APB counts from Holter reports were converted to a frequency per 24 hours for each patient. The primary outcome was detection of ≥1 episodes of atrial fibrillation or flutter lasting ≥30 s by 30-day ECG monitoring or clinically within 90 days postrandomization. Secondary outcomes were AF ≥30 s detected by 30-day ECG, AF ≥2.5 minutes detected by 30-day ECG, and AF detected by any means within 2 years of clinical follow-up. AF events were adjudicated centrally by a cardiologist and internist blinded to patient details; any disagreements were resolved with an independent cardiologist.
Statistical Analysis
We used multivariable logistic regression analysis, restricted to the intervention group, to assess the association between preplanned baseline variables on the primary and secondary outcomes of AF detection. Because of the small number of outcome events, we had to limit the number of variables included in the model. We chose the following variables based on previous studies, such as (1) baseline APB count (the primary exposure of interest), defined as the number of APBs/24 h recorded on the prestudy Holter monitor ordered clinically as part of usual care after the index stroke or TIA, (2) the number of Holterdetected runs of nonsustained atrial tachycardia/24 h (≥4 continuous nonsinus beats of atrial origin), (3) age, and (4) left atrial enlargement by echocardiography, defined as diameter ≥40 mm or volume index >29 mL/m 2 or by qualitative description. Nonlinear associations between APB count and the log-odds of the outcome was modeled using a restricted cubic spline with 3 knots. Three knots were chosen given the sample size and as the relationships were expected to change smoothly and gradually. The bootstrap was used to evaluate overfitting and produce corrected indexes of discrimination. Furthermore, we categorized patients into 5 groups based on their baseline 24-hour APB count: <100, 100 to 499, 500 to 999, 1000 to 1499, and ≥1500.
Results
Among 287 participants randomized to wear the 30-day ECG monitor, 280 underwent any duration of monitoring or completed 90-day follow-up, and APB data were available on baseline Holter reports for 237 participants. The qualifying event was a cryptogenic ischemic stroke in two thirds and a cryptogenic TIA in one third. Mean age was 72.2±8.6 years, 46% were women (n=110), 89% were white (n=212), 71% had hypertension (n=168), and 16% had previous stroke(s) before the index event (n=39). The median CHADS 2 (congestive heart failure, hypertension, age, diabetes, prior stroke/transient ischemic attack) score was 3 points (interquartile range [IQR], [3] [4] .
The median baseline APB count was 66 (IQR, 18-309) in the entire cohort, and it was higher in patients who were subsequently found to have AF (629 beats/24 h [IQR, ) compared with those without AF (45 beats/24 h [IQR, ), P<0.001 (Wilcoxon rank sum test).
In the regression model, APB count was the only statistically significant predictor of the primary outcome of AF detection (P=0.0017 overall; nonlinear component P=0.0009; see online-only Data Supplement for additional details). The predicted probability of AF increased steadily with increasing by guest on April 20, 2017 http://stroke.ahajournals.org/ Downloaded from APB count up to ≈1500 APBs/24 h, above which there was a plateau (Figure 1 ). Similar results were obtained for the secondary outcome of AF ≥30 s on the 30-day ECG monitor alone (P<0.0001) and the more robust outcome of AF ≥2.5 minutes on 30-day ECG (P=0.0005), and for AF detection by any means at 2 years (P=0.0027).
For the primary outcome, the AF detection rate in the intervention group was 16% overall but it was highly dependent on the baseline APB count: the predicted probability of AF was 7% to 9% in patients with <100 APBs/24 h, 9% to 24% in those with 100 to 499 APBs/24 h, 25% to 37% in those with 500 to 999 APBs/24 h, 37% to 40% in those with 1000 to 1499 APBs/24 h, and it reached a plateau ≈40% in those with ≥1500 APBs/24 h. Clinicians can refer to Table to estimate an individual patient's probability of AF based on the number of APB (see Figure I in the online-only Data Supplement for computational formula).
Discussion
In this analysis from EMBRACE, the largest AF detection trial in patients with cryptogenic stroke, we found that the number of Holter-detected APBs was a strong independent predictor of AF. The overall 90-day AF detection rate in this cohort was 16%, and the baseline APB count stratified the probability of AF into low-, moderate-, or high-risk categories, ranging from 7% to 40%. The average baseline APB count among our stroke patients who subsequently had AF detected was 14 times higher than in the stroke patients without AF detected, and 10-fold higher than in the general population where the median APB count/24 h is 60 (IQR, 19-228) among individuals aged ≥65 years and 62 (IQR, 29-156) among those aged ≥70 years. 18, 21 These results validate and extend smaller observational stroke studies that relied on arbitrary dichotomized APB counts, and we provide a practical reference table for clinicians to estimate a patient's probability of AF for a given APB count (Table) . The relationship between APB count and the probability of subclinical AF was dose-dependent and nonlinear, similar to that reported for clinical AF in a longitudinal study over a median follow-up of 13 years, 18 and there was no lower APB threshold below which AF could be excluded.
Our findings support the concept that frequent APB represent a proarrhythmic tendency and are a marker of prevalent subclinical AF, in addition to being a precursor of incident AF. [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] 20, 22, 23 Several recent studies indicate that Holterdetected frequent APBs, or APBs present on a routine 12-lead ECG, 19, 20 are an independent risk factor for stroke or death; previous studies used different thresholds for defining frequent APBs during a 24-hour recording (>100, 16 >218, 14 >228 APBs, 18 or >720 APBs or episodes of atrial tachycardia >20 beats long 15 ). In our study, we found that nearly 50% patients with cryptogenic stroke had an APB frequency >720/24 h, which is potentially clinically important based on the above literature. 15 However, as the aforementioned studies did not use any sensitive long-term monitoring for AF, it is unclear whether the increased stroke or death risks were because of subsequent development of AF. Two cohort studies in pacemaker patients demonstrated that subclinical AF as brief as 5 or 6 minutes in duration is associated with an increased risk of stroke. 24, 25 However, many strokes in the pacemaker studies occurred without the development of longer-lasting AF episodes or lacked a temporal association with the AF episodes. 26, 27 Such observations suggest that brief atrial arrhythmias or frequent APBs may be a stroke risk marker independent of causal mechanisms, such as the development of long-lasting AF.
This research has practice implications for secondary stroke prevention. The findings are clinically relevant because 1 in every 4 ischemic stroke patients (and half of TIA patients) are labeled as cryptogenic 28 yet a substantial proportion will have undetected and untreated AF.
1-3 Prolonged ambulatory 7 Because prolonged monitoring can be costly, difficult to access in some regions, and burdensome for some patients, appropriate selection of patients and monitoring strategy is needed. Both noninvasive and minimally invasive monitoring technologies for AF detection are available, and our data suggest that any approach will be most effective, and cost-effective, when applied to patients with frequent APBs. Our findings may be particularly pertinent to patient selection for costly implantable ECG monitors or repeated noninvasive monitoring over time. Patients with excessive APB who do not have AF detected in the short term may benefit from longer-term surveillance for AF.
In light of our study results, we propose a tiered approach for detecting subclinical AF in patients being investigated after an embolic stroke or TIA ( Figure 2 ). We suggest 24-hour Holter ECG as an initial screen. If AF is not detected and the patient meets criteria for an embolic stroke of undetermined source 28 and is considered an appropriate candidate for additional monitoring and potential anticoagulation (and is not being anticoagulated empirically or randomized in an anticoagulant trial), then we suggest additional noninvasive ECG monitoring using a device capable of continuous recording (mobile outpatient telemetry) or an AF auto-detect loop recorder (note that traditional patient-triggered event recorders that only capture symptomatic episodes will miss subclinical AF). In terms of the target monitoring duration, we suggest 4 weeks of monitoring for patients with frequent APBs; 2 weeks may be reasonable for patients with infrequent APBs given the present analysis and the fact that most AF cases in the EMBRACE trial were detected within the first 2 weeks of monitoring. 4 A threshold of >500 APBs/24 h seems to be a reasonable pragmatic definition for frequent APBs in this population based on the data from this study. For patients with excessive APBs (eg, >1000 APBs/24 h), if AF is not documented after 4 weeks of monitoring then we would consider further monitoring. The role of empiric anticoagulant therapy for patients with frequent APBs, but without documented AF, is currently unknown; randomized trials of anticoagulation for cryptogenic stroke are currently underway and hopefully will evaluate subgroups with frequent APBs. 29, 30 This study has several limitations. The sample size could not support the evaluation of additional predictor variables, such as neuroimaging features. Our results reflect detection of AF based on 30-day monitoring in an older, predominantly white, Canadian population. Longer monitoring would have yielded more AF and our 2-year AF rate, therefore, is probably an underestimate. 5 Most of the study monitor-detected AF was brief and subclinical, and may or may not have been causally related to the index stroke, but nevertheless represents a potentially treatable risk factor for recurrent stroke. 7, 24, 31, 32 Increasing age is known to be associated with a greater likelihood of both clinical and subclinical AF, 4,33 but we found that age was not a significant predictor when APB count is included in the model. However, we did not study patients aged <55 years so the ability to fully assess the effect of age was limited. Also, because most echocardiograms from our study sites reported only atrial diameter, not volume, we probably underestimated atrial size and, therefore, limited the ability of our model to assess the significance of left atrial enlargement, a known predictor of clinical AF. 34, 35 In summary, the EMBRACE AF prediction formula enables simple, rapid, and powerful AF risk stratification, and external validation in other, more diverse cohorts is needed. It has potential for widespread applicability for patient care because it requires only a 24-hour ECG recording, without needing to rely on echocardiography, MRI, or biomarkers, because APB counts are routinely reported on Holter and other continuous outpatient ECG monitor studies. Holter monitoring is widely available and already recommended as a first-line diagnostic investigation after stroke or TIA 28 ; this APB count up to ≈1500 APBs/24 h, above which there was a plateau (Figure 1 ). Similar results were obtained for the secondary outcome of AF ≥30 s on the 30-day ECG monitor alone (P<0.0001) and the more robust outcome of AF ≥2.5 minutes on 30-day ECG (P=0.0005), and for AF detection by any means at 2 years (P=0.0027).
Our findings support the concept that frequent APB represent a proarrhythmic tendency and are a marker of prevalent subclinical AF, in addition to being a precursor of incident AF. [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] 20, 22, 23 Several recent studies indicate that Holterdetected frequent APBs, or APBs present on a routine 12-lead ECG, 19, 20 are an independent risk factor for stroke or death; previous studies used different thresholds for defining fre- 16 14 5 or 6 minutes in duration is associated with an increased risk of stroke. 24, 25 However, many strokes in the pacemaker studies occurred without the development of longer-last- 
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ECG monitoring significantly improves AF detection compared with the usual practice of short-term ECG monitoring, enabling initiation of anticoagulant therapy aimed at preventing recurrent disabling or fatal strokes. New practice guidelines now call for prolonged ECG monitoring to evaluate patients with cryptogenic stroke or TIA, yet the recommended duration of monitoring varies across different guidelines, ranging from ≥1 weeks 2 to ≈30 days 8 or additional ambulatory monitoring of unspecified duration. 7 Because prolonged monitoring can be costly, difficult to access in some regions, and burdensome for some patients, appropriate selection of patients and monitoring strategy is needed. Both noninvasive and minimally invasive monitoring technologies for AF detection are available, and our data suggest that any approach will be most effective, and cost-effective, when applied to patients with frequent APBs. Our findings may be particularly pertinent to patient selection for costly implantable ECG monitors or repeated noninvasive monitoring over time. Patients with excessive APB who do not have AF detected in the short term may benefit from longer-term surveillance for AF.
In light of our study results, we propose a tiered approach for detecting subclinical AF in patients being investigated after an embolic stroke or TIA (Figure 2 ). We suggest 24-hour Holter ECG as an initial screen. If AF is not detected and the patient meets criteria for an embolic stroke of undetermined source 28 and is considered an appropriate candidate for additional monitoring and potential anticoagulation (and is not being anticoagulated empirically or randomized in an anticoagulant trial), then we suggest additional noninvasive ECG monitoring using a device capable of continuous recording (mobile outpatient telemetry) or an AF auto-detect loop recorder (note that traditional patient-triggered event recorders that only capture symptomatic episodes will miss subclinical AF). In terms of the target monitoring duration, we suggest 4 weeks of monitoring for patients with frequent APBs; 2 weeks may be reasonable for patients with infrequent APBs given the present analysis and the fact that most AF cases in the EMBRACE trial were detected within the first 2 weeks of monitoring. 4 A threshold of >500 APBs/24 h seems to be a reasonable pragmatic definition for frequent APBs in this population based on the data from this study. For patients with excessive APBs (eg, >1000 APBs/24 h), if AF is not documented after 4 weeks of monitoring then we would consider further monitoring. The role of empiric anticoagulant therapy for patients with frequent APBs, but without documented AF, is currently unknown; randomized trials of anticoagulation for cryptogenic stroke are currently underway and hopefully will evaluate subgroups with frequent APBs. 29, 30 This study has several limitations. The sample size could not support the evaluation of additional predictor variables, such as neuroimaging features. Our results reflect detection of AF based on 30-day monitoring in an older, predominantly white, Canadian population. Longer monitoring would have yielded more AF and our 2-year AF rate, therefore, is probably an underestimate. 5 Most of the study monitor-detected AF was brief and subclinical, and may or may not have been causally related to the index stroke, but nevertheless represents a potentially treatable risk factor for recurrent stroke. 7, 24, 31, 32 Increasing age is known to be associated with a greater likelihood of both clinical and subclinical AF, 4,33 but we found that age was not a significant predictor when APB count is included in the model. However, we did not study patients aged <55 years so the ability to fully assess the effect of age was limited. Also, because most echocardiograms from our study sites reported only atrial diameter, not volume, we probably underestimated atrial size and, therefore, limited the ability of our model to assess the significance of left atrial enlargement, a known predictor of clinical AF. 34, 35 In summary, the EMBRACE AF prediction formula enables simple, rapid, and powerful AF risk stratification, and external validation in other, more diverse cohorts is needed. It has potential for widespread applicability for patient care because it requires only a 24-hour ECG recording, without needing to rely on echocardiography, MRI, or biomarkers, because APB counts are routinely reported on Holter and other continuous outpatient ECG monitor studies. Holter monitoring is widely available and already recommended as a first-line diagnostic investigation after stroke or TIA 28 ; this study affirms its value 
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ECG monitoring significantly improves AF detection compared with the usual practice of short-term ECG monitoring, enabling initiation of anticoagulant therapy aimed at preventing recurrent disabling or fatal strokes. New practice guidelines now call for prolonged ECG monitoring to evaluate patients with cryptogenic stroke or TIA, yet the recommended duration of monitoring varies across different guidelines, ranging from ≥1 weeks 2 to ≈30 days 8 or additional ambulatory monitoring of unspecified duration. 7 Because prolonged monitoring can be costly, difficult to access in some regions, and burdensome for some patients, appropriate selection of patients and monitoring strategy is needed. Both noninvasive and minimally invasive monitoring technologies for AF detection are available, and our data suggest that any approach will be most effective, and cost-effective, when applied to patients with frequent APBs. Our findings may be particularly pertinent to patient selection for costly implantable ECG monitors or repeated noninvasive monitoring over time. Patients with excessive APB who do not have AF detected in the short term may benefit from longer-term surveillance for AF. In light of our study results, we propose a tiered approach for detecting subclinical AF in patients being investigated after an embolic stroke or TIA (Figure 2 ). We suggest 24-hour Holter ECG as an initial screen. If AF is not detected and the patient meets criteria for an embolic stroke of undetermined source 28 and is considered an appropriate candidate for additional monitoring and potential anticoagulation (and is not being anticoagulated empirically or randomized in an anticoagulant trial), then we suggest additional noninvasive ECG monitoring using a device capable of continuous recording (mobile outpatient telemetry) or an AF auto-detect loop recorder (note that traditional patient-triggered event recorders that only capture symptomatic episodes will miss subclinical AF). In terms of the target monitoring duration, we suggest 4 weeks of monitoring for patients with frequent APBs; 2 weeks may be reasonable for patients with infrequent APBs given the present analysis and the fact that most AF cases in the EMBRACE trial were detected within the first 2 weeks of monitoring. 4 A threshold of >500 APBs/24 h seems to be a reasonable pragmatic de population based on the da excessive APBs (eg, >100 mented after 4 weeks of m further monitoring. The ro for patients with frequent A is currently unknown; rand cryptogenic stroke are cur evaluate subgroups with fr This study has several not support the evaluation such as neuroimaging fea of AF based on 30-day mo white, Canadian populatio yielded more AF and our 2 an underestimate. 5 Most of brief and subclinical, and related to the index stroke, tially treatable risk factor fo age is known to be associa clinical and subclinical AF a significant predictor wh model. However, we did n the ability to fully assess because most echocardiog only atrial diameter, not vo atrial size and, therefore, assess the significance of l dictor of clinical AF. 34, 35 In summary, the EMBR simple, rapid, and powerf nal validation in other, mo potential for widespread ap it requires only a 24-hour rely on echocardiography, counts are routinely repor outpatient ECG monitor s available and already reco investigation after stroke o 
